Background: The effectiveness of bronchial thermoplasty (BT) has been reported in patients with severe asthma, yet its effect on different bronchial structures remains unknown. Objective: We sought to examine the effect of BT on bronchial structures and to explore the association with clinical outcome in patients with severe refractory asthma. Methods: Bronchial biopsy specimens (n 5 300) were collected from 15 patients with severe uncontrolled asthma before and 3 months after BT. Immunostained sections were assessed for airway smooth muscle (ASM) area, subepithelial basement membrane thickness, nerve fibers, and epithelial neuroendocrine cells. Histopathologic findings were correlated with clinical parameters. Results: BT significantly improved asthma control and quality of life at both 3 and 12 months and decreased the numbers of severe exacerbations and the dose of oral corticosteroids. At 3 months, this clinical benefit was accompanied by a reduction in ASM area (median values before and after BT, respectively: 19.7% 
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Severe asthma is characterized by persistent symptoms and frequent exacerbations that contribute to the mortality and morbidity associated with this disease. 1 The heterogeneity of airway inflammation in patients with severe asthma has led to the recognition of multiple distinct endotypes, allowing the use of novel specific biologics, such as anti-IgE and anti-IL-5 mAbs.
2,3 These biologics are indicated for patients whose asthma remains uncontrolled, despite high doses of inhaled corticosteroids, long-acting bronchodilators, and oral corticosteroids (OCSs). 4, 5 However, some patients experience severe exacerbations despite treatment with these biologics or even with undetectable inflammation. 6 Recent studies conducted in asthmatic children demonstrated that structural changes of the airway wall, known as airway remodeling, arise independently on inflammation. 7 Remodeling in asthmatic patients is manifested as epithelial cell hyperplasia, goblet cell metaplasia, subepithelial fibrosis, angiogenesis, and increase in airway smooth muscle (ASM) mass. 8, 9 These changes correlate with asthma severity and the degree of airflow obstruction. 8, 9 Bronchial thermoplasty (BT) is an endoscopic procedure that targets primarily airway remodeling by delivering temperaturecontrolled radio frequency energy to the airway wall. Clinical trials of BT in patients with moderate-to-severe asthma have reported improvement of quality of life and reduction in the number of exacerbations. [10] [11] [12] However, which patients could benefit from BT is still unknown, and the mechanisms underlying clinical improvement are currently under debate. 13, 14 A reduction in ASM mass after BT has been demonstrated recently in patients with severe uncontrolled asthma, 15 yet the relationship with clinical benefit remains elusive. Furthermore, because heat energy produced during BT can potentially alter airway structural components other than the ASM, additional mechanisms might contribute to the observed clinical efficacy.
The current study addresses these important issues by performing a detailed quantitative analysis of major structural airway alterations and mucosal inflammation in patients with severe asthma undergoing BT and by correlating the observed modifications with key clinical outcomes.
METHODS Subjects
Fifteen adult patients (27-69 years of age) who met the American Thoracic Society criteria for severe refractory asthma (American Thoracic Society/ European Respiratory Society criteria) 16 were recruited at the Pneumology A Department of the Bichat University Hospital (Paris, France) between January and December 2013 (Table I) . Selection criteria were patients with uncontrolled severe asthma, as assessed by an Asthma Control Test (ACT) score of 15 or less, despite optimal management and maximal medications for at least 12 months before entry; prebronchodilator FEV 1 greater than 30% and less than 80% of predicted values; and at least 3 exacerbations, which were defined as a worsening of asthma symptoms requiring treatment with an OCS during the previous year. Ten patients met the criteria for receiving the anti-IgE mAb omalizumab for 6 months before entry into the protocol without successful clinical outcome. For these 10 patients, discontinuation of omalizumab occurred at least 6 months before the first BT session (patient's details are provided in the Methods section in this article's Online Repository at www. jacionline.org).
Before and 3 and 12 months after BT, all subjects underwent assessment of FEV 1 and forced vital capacity (FVC) before and after inhalation of 400 mg of salbutamol. ACT (response scale, and Asthma Quality of Life Questionnaire (AQLQ; response scale, 1-7) scores, [17] [18] [19] numbers of exacerbations, hospitalizations for asthma and intensive care unit (ICU) visits, emergency department visits, and treatments were recorded throughout the study.
The protocol was approved by the CPP Ile-de-France I Ethics Committee (no. 2012-sept-13003), and all subjects provided written informed consent. This trial is registered on ClinicalTrials.gov NCT01777360.
BT procedure
BT was performed with the Alair System (Boston Scientific, Marlborough, Mass), as previously described (details are provided in the Methods section in this article's Online Repository). [10] [11] [12] All patients underwent 3 sessions of BT separated by 1-month intervals. 15 A median of 44 (25th-75th interquartile range [IQR], 37-57), 57 (25th-75th IQR, 52-64), and 46 (25th-75th IQR, 43-78) heat activations were administered during the first, second, and third BT sessions in the right lower lobe, left lower lobe, and 2 upper lobes, respectively. No heat activation was delivered in the middle lobe. 15 
Bronchoscopy and biopsy collection
A bronchoscopy was performed 15 days before the first BT procedure and 3 months after the last procedure by the same operator (M.-C.D.). 15, 20 Ten bronchial biopsy specimens were collected at the same locations: 3 biopsy specimens from the right lower lobe (B7-B8, B8-B9, and B9-B10), 2 biopsy specimens from each upper lobe (B1-B2 and lingula), 2 biopsy specimens from the middle lobe (B4-B5), and 3 biopsy specimens from the left lower lobe (B7-B8, B8-B9, and B9-B10). 15 
Histopathologic studies
Histopathologic analyses were performed blind at the Unit of Airway Inflammation, Lund University, Sweden (methodological details are provided in the Methods section in this article's Online Repository at www.jacionline. org). Briefly, automated immunohistochemistry was performed, as previously described, 21, 22 with a Dako Cytomation staining robot and the antibodies listed in Table E1 in this article's Online Repository at www.jacionline.org. Stained sections were digitalized and analyzed with computerized image analysis software. ASM area was manually delineated under guidance of a-smooth muscle actin immunostaining. 15, 20 Neuroendocrine epithelial cells, as defined by their distinct protein gene product (PGP) 9.5 1 nuclei, were manually counted and normalized to the epithelial surface area. Immunoreactivity for PGP9.5 1 nerve fibers, blood and lymph vessels, eosinophils, and neutrophils was calculated by dividing the positive staining for each marker (as determined by a positive pixel count algorithm) with the total tissue area (total pixels) (see Figs E1-E3 in this article's Online Repository at www.jacionline.org). Epithelial morphologic status was qualitatively assessed on hematoxylin-stained sections, as described previously. 23 Finally, collagen was stained with Masson trichrome dye, and its extent and intensity were quantified. Subepithelial basement membrane (SBM) thickening was determined by using multiple point-to-point measurements, with approximately 50-mm intervals between each measurement.
All examinations, which were performed on blind sections, were assessed in the 10 lung biopsy specimens obtained before BT, and values were compared with those obtained in the 8 biopsy specimens from the BT-treated lung lobes at 3 months after treatment and to the 2 biopsy specimens from the BT-untreated middle lobe. Decoding of tissue sections took place once all analyses were completed.
In separate analyses values obtained at 3 months in biopsy specimens from the middle BT-untreated lung lobe were compared with those obtained at the same time in the BT-treated lung lobes and with values detected in the 10 biopsy specimens collected before BT.
Statistical analyses
Qualitative variables are shown as numbers and percentages. Quantitative variables are reported as mean values and SDs, except where otherwise indicated. We used linear regression models to compare the values of biological and clinical variables measured at the 3 time points: before and 3 and 12 months after BT. When the normality and homogeneity of variance assumptions were not satisfied, variables were replaced by their logtransformed values. The number of events was compared between study groups with the use of Poisson regression with correction for treatment exposure and overdispersion. The models described above included both fixed (time) and random (patient) effects to account for serial measurements made in the same patients (mixed-effect models). Because some variables included a large proportion of zero values, pattern mixtures models were used. In addition, because multiple hypotheses were tested, the Benjamini and Hochberg procedure has been used to adjust P values for multiple comparisons. Potential associations between histochemical and morphometric variables were assessed by using nonparametric Spearman rank correlation (r). All tests were 2-tailed; P values of less than .05 were considered significant. Data were analyzed statistically with R 2.15.2 (R Foundation for Statistical Computing, Vienna, Austria) software.
RESULTS

Clinical effects of BT
Clinical and airway functional parameters were examined before and 3 and 12 months after BT (Table I ). Although 6 of the 15 BT-treated patients with severe asthma still experienced uncontrolled asthma at 3 months, we found overall significantly higher scores on the ACT and AQLQ (P < .001 for both comparisons) and a lower number of severe exacerbations (P < .001), visits to the emergency department (P < .001), hospitalization for asthma (P < .01), and ICU visits (P < .001) than those measured before BT (Table I) .
The clinical benefit observed at 3 months persisted at 12 months (Table I) . Indeed, a significant decrease in the number of exacerbations (P < .001), hospitalizations for asthma (P < .001), ICU visits (P 5 .008), and emergency department visits (P < .001) and an increase in ACT and AQLQ scores (P < .001 for both comparisons) were observed at 12 months compared with values obtained before BT. In addition, at 12 months, 8 of the 10 patients still required regular OCSs, and the mean daily dose of oral prednisone was significantly lower compared with that administered at entry (13.8 vs 31.5 mg/d 12 months after compared with before BT, P 5 .002, Table I ).
Twelve months after BT, 4 of the 15 patients still had uncontrolled asthma, with a mean ACT score of 7.8 and an AQLQ score of 2.4 (see Table E2 in this article's Online Repository at www.jacionline.org). Patients were considered BT unresponsive when ACT scores at 3 and 12 months after BT remained lower than 15. Although in these 4 poorly responsive patients BT decreased the number of severe exacerbations by approximately 80%, values remained statistically higher than those observed in BT-responsive asthmatic patients (P < .01, see Table E2 ). The 4 poorly responsive patients still required OCSs 12 months after BT at a daily dose significantly higher than that required by the 6 patients among the 11 responders who were still receiving OCSs (see Table E2 ). BT was not associated with changes in blood eosinophil counts and pulmonary function test results at both 3 and 12 months (Table I) .
Histopathologic effects of BT
At baseline, ASM area ranged from 9.1% to 30.3% of the mucosal area (median, 19.7%; 25th-75th IQR, 16.2% to 21.8%). BT resulted in a significant decrease in ASM area at 3 months, with a median value of 5.2% (25th-75th IQR, 3.7% to 9.8%; P < .001; Fig 1, A, and exemplified in Fig 2, A and B) . This decrease was accompanied by a significantly larger biopsy area stained for collagen and by an intensification of its expression (see Fig E4 in this article's Online Repository at www.jacionline.org).
We then determined whether BT altered SBM thickening, blood and lymphatic vessels, submucosal and ASM-associated nerve fibers, and mucosal granulocytes (Fig 1, A-I) .
BT marginally but significantly decreased SBM thickening (median values before and 3 months after BT of 4.4 and 3.9, respectively; P 5 .02; Fig 1, B) , without modifying significantly the density of blood and lymphatic vessels (Fig 1, C and D) . Submucosal and ASM-associated nerve fibers were significantly reduced 3 months after BT compared with values measured before BT. Indeed, submucosal nerves amounted to 1.0 ‰ (25th-75th IQR, 0.7-1.3 ‰) immunoreactivity and 0.3 ‰ (25th-75th IQR, 0.1-0.5 ‰) immunoreactivity before and after BT, respectively (P < .001), and values of ASM-associated nerves were of 452. 6 ) before and after BT, respectively (P 5 .02; Fig 1, E and F) .
Subepithelial mucous glands (Fig 1, G) , eosinophils, and neutrophils (Fig 1, H and I) were not significantly modified by BT.
Finally, we examined whether BT targeted the bronchial epithelium (Fig 1, J-O) . Neither the proportion of regenerating bronchial epithelium or normal stratified columnar, metaplastic, or squamous epithelium (Fig 1, J-M) nor goblet cell hypertrophy/hyperplasia (Fig 1, N) were modified by BT. In contrast, we observed a significant reduction (P 5 .02) in the numbers of epithelial neuroendocrine PGP 1 cells (Fig 1, O) . Hence whereas these cells were clearly present in the bronchial epithelium from 11 of the 15 patients with severe asthma at inclusion, with a median value of 4.9 cells/mm 2 (25th-75th IQR, 0.3-14.1 cells/mm 2 ) in the epithelial layer, they were detectable only in 2 patients 3 months after BT (Fig 1, O) .
We previously reported that BT decreased ASM area also in the heat-untreated middle lobe in 50% to 70% of patients with severe asthma. 15 Therefore we determined whether this same effect was observed on the hallmarks of airway inflammation and remodeling currently investigated (see Table E3 in this article's Online Repository at www.jacionline.org). We found a trend toward a decrease in submucosal and ASM-associated nerves and in the proportion of glandular tissue in the BT-untreated middle lobes (see Table E3 ). A significant reduction in the number of neuroendocrine epithelial cells (P 5 .04) was also observed in the BT-untreated middle lobes at 3 months compared with values obtained in all lung lobes before BT (see Table E3 ). In these analyses 4 variables were characterized by a large number of zero values in addition to continuous positive values: glandular tissue, number of PGP 1 neuroendocrine cells, regenerating epithelium, and squamous metaplastic epithelium. The use of pattern mixture models using logistic and truncated Poisson distributions instead of nonparametric tests yielded similar results for these 4 variables (see Table E3 ).
Because 4 of the 15 patients with severe asthma showed limited clinical improvement on BT at 12 months, we compared their degree of airway remodeling at 3 months with that observed in BT-responsive patients (Fig 3) . Asthmatic patients poorly responsive to BT had a median value of ASM area of 14.6% compared with 5.7% observed in the remaining 11 patients with severe asthma (P 5 .05; Fig 3, A) . Submucosal and ASM-associated nerves were similarly downregulated in BT-responsive and poorly responsive patients (Fig 3, C and D) , and no detectable differences were found in SBM thickening (Fig 3, B) and other hallmarks of airway remodeling or granulocyte infiltration (data not shown). Finally, median numbers of neuroendocrine cells per square millimeter of bronchial epithelium was 3.2 in the 4 patients poorly responsive to BT, whereas these cells were undetectable in the rest of the patients (P 5 .05).
Correlation analyses
Multiple correlation analyses conducted before and 3 months after BT demonstrated significant positive associations between ASM area and submucosal and ASM-associated nerves and epithelial neuroendocrine cells (see Table E4 Changes in histopathologic parameters induced by BT were not associated with the cumulative numbers of heat stimulations administered during the 3 sessions (see Table E5 in this article's Online Repository at www.jacionline.org).
We then investigated the relationship between the components of airway remodeling that were altered 3 months after BT and clinical parameters at 3 and 12 months (Table II and see Tables  E6-E10 in this article's Online Repository at www.jacionline. org). Three months after BT, ASM correlated highly significantly with ACT scores (P 5 .003) and numbers of severe exacerbations (P < .001), emergency department visits (P 5 .003), and hospitalizations for asthma (P 5 .03, Table II ). Similar associations were seen when considering submucosal and ASM-associated nerves and numbers of epithelial neuroendocrine cells, whereas SBM thickening correlated exclusively with ACT scores (Table II) . In a prospective analysis we found that most of these correlations were maintained at 12 months (Table II) .
The histopathologic parameters presently investigated did not correlate with prebronchodilator and postbronchodilator FEV 1 , FVC, and FEV 1 /FVC ratio at 3 months (see Tables E6-E10) .
DISCUSSION
The present study was aimed at investigating the clinical benefit of BT in patients with severe refractory asthma and at BT significantly improved asthma control, as assessed by daily symptoms (ACT; 152%), rate of severe exacerbations, hospitalizations for asthma, ICU stays, and emergency department visits. These effects were accompanied by a significant reduction in maintenance doses and numbers of OCS bursts and improvements in AQLQ (162%) scores at 12 months. Clinical benefit was detectable at 3 months after BT and persisted until 12 months. Although supporting in part earlier observations found in patients with severe asthma, [10] [11] [12] 24, 25 it should be emphasized that our patients with severe asthma were more symptomatic than those enrolled in earlier studies, with a mean rate of exacerbations during the year before entry of 9.7 instead of 0.7, a mean AQLQ score of 2.6 instead of 4.7, and a greater prevalence of maintenance use of OCSs (67% instead of 41%). 11, 12 Therefore clinical improvement at 12 months currently reported in the present study was of a greater magnitude than that previously shown, with a 92% decrease in the number of exacerbations, a 90% lower number of emergency department visits, 88% less hospitalizations for asthma and ICU visits, and 93% and 62% improvement in ACT and AQLQ scores, respectively. Because we did not include a sham control group in the current study, we cannot rule out that subjects FIG 2 . Structural effects of BT in bronchial biopsy specimens from patients with severe asthma. Bright-field micrographs of bronchial biopsy specimens subjected to quadruple immunohistochemical staining for smooth muscle actin (red), the vascular endothelial marker CD31 (green), lymph endothelial marker, podoplanin (D2-40, brown), and the neuronal marker PGP.9.5 (black) are shown. A and B, Biopsy specimens taken before and 3 months after BT, respectively (note that Fig 2, B, rather than representing the average, exemplifies a case in which smooth muscle was virtually absent). C, A neuroendocrine cell (NEC) in the bronchial epithelium detected based on nuclear distribution of PGP (arrowhead). D and E, Subepithelial nerves (arrowheads) in the subepithelial region before (Fig 2, D) and after (Fig 2, E) BT. F, Smooth muscle-associated nerves (arrowhead) exemplified in a biopsy specimen collected before BT treatment. Scale bars 5 250 mm (Fig 2, A and B) or 40 mm (Fig 2, C-F) . sm, Smooth muscle; bv, blood vessels; lv, lymphatic vessels. became more adherent to treatments on BT compared with the 12 months before enrollment. However, this is very unlikely because all the patients were part of the French longitudinal COBRA cohort, in which a follow-up is scheduled every 6 months. As shown in Table E11 in this article's Online Repository at www.jacionline.org, the clinical characteristics (ACT and exacerbations) of 20 patients with severe asthma belonging to the COBRA cohort are identical to those of the 15 subjects who underwent the 3 BT sessions. In these 20 patients with severe asthma who could be considered a control group, clinical parameters remained stable over 1 year, making drug adherence an explanation for the clinical improvement observed after BT unlikely. Histopathologic examination of bronchial biopsy specimens collected 3 months after BT showed a significant reduction in ASM area (73%), thereby extending our previous results 15 and confirming those recently obtained by Chakir et al. 26 This reduction in ASM area correlated statistically with the improvement in asthma control and quality of life and the decrease in severe exacerbations, hospitalizations, and visits to the emergency department for asthma at 3 months. Importantly, all correlations were maintained at 1 year after BT. No association between clinical improvement and histologic parameters was reported by Chakir et al. 26 In this report bronchial biopsy specimens were collected in 17 subjects during the first BT session from the nontreated lobe (the left lower lobe), with BT being performed in the right lower lobe. During their second treatment, which occurred at 3 to 14 weeks (median, 3 weeks), all 17 subjects underwent biopsies of the previously treated right lobe. However, only 9 of 17 patients underwent biopsies of the right lower lobe during the third BT procedure (7-22 weeks; median, 8 weeks). In our current study all subjects underwent systematic biopsy specimens (10 in all lung lobes) before and 3 months after the third BT procedure. This might explain why Chakir et al did not find correlations between BT-induced changes in ASM area and clinical improvement at 1 year. We also found that collagen deposition in the bronchial submucosa (both the extent and intensity of the expression) increased in parallel with the reduction in ASM area. Whether this extracellular matrix synthesis occurs in response to BT-induced tissue injury and its precise composition remain to be determined. Of note, Chakir et al 26 reported a decrease in type 1 collagen deposition underneath the SBM after BT. Further studies are needed to determine which types of collagen are affected by BT and its precise localization in the bronchial submucosa.
Supporting previous observations, 11, 12, 24 BT did not alter prebronchodilator and postbronchodilator FEV 1 and FVC.
Studies conducted in dogs and patients scheduled for lung resection have shown that BT selectively ablated ASM. 27, 28 In the current report we found that BT slightly but significantly reduced SBM thickening, without altering blood and lymphatic vessels and mucous glands, indicating that this procedure did not target other key components of airway remodeling associated with severe asthma. 20, 29, 30 The parasympathetic nervous system is an important constrictor neural pathway that controls airway tone. 31 Stimulation of cholinergic nerves causes bronchoconstriction, mucus secretion, and bronchial vasodilation. 32 We found that autonomic nerve fibers, both in the bronchial submucosa and within the ASM bundles, were drastically decreased 3 months after BT. This Overall P values were less than .01 (Fig 3, A) , .31 (Fig 3, B) , less than .01 (Fig 3, C) , .06 (Fig 3, D) , and less than .01 (Fig 3, E ; Kruskal-Wallis test). *P < .05 compared with values obtained before BT and P < .05 compared with patients responsive to BT, Student t test for paired values.
reduction was significantly associated with the decrease in the number of severe exacerbations, suggesting that damage of autonomic-innervated structures induced by BT downregulated airway excitability and thus improved asthma control. Because the bronchial epithelium could be damaged by the heat shock induced by BT, we performed a morphologic analysis of the epithelium, as previously done 23 before and 3 months after BT. Neither epithelial regeneration, epithelial metaplasia, nor the extent of normal stratified columnar epithelium was modified by BT. These findings indicate that if epithelial injury occurred, it was very early after heat delivery and that the absence of visible morphologic alterations observed at 3 months suggests that the repair process has already been completed. Although BT might alter the functional capacities of the bronchial epithelium without modifying its structure visually, this hypothesis remains to be explored.
Neuroendocrine cells are specialized epithelial cells distributed throughout the bronchial tree as solitary cells or as innervated clusters (neuroepithelial bodies). 33 These cells drive fetal lung growth and differentiation through paracrine secretion of bioactive amines, neuropeptides, and growth factors, including serotonin, substance P, neurokinin A, bombesin, and calcitonin gene-related peptide. 33 In addition, they function as intrapulmonary hypoxia-sensitive chemoreceptors, thereby contributing to control of airway tone. 33, 34 Although the presence of pulmonary neuroendocrine cells in normal airways has been illustrated, 35 their possible role in the pathogenesis of asthma has not been clearly demonstrated. We found that BT decreased by approximately 95% the number of neuroendocrine epithelial cells at 3 months. This decrease highly correlated with the improvement in asthma control (ACT and AQLQ scores), number of exacerbations, hospitalization for asthma and ICU stays, and emergency department visits. These data indicate that epithelial neuroendocrine cells are also a valuable hallmark of the beneficial clinical effects of BT.
Surprisingly, we also found that the number of neuroendocrine cells was downregulated in the middle lobe, which was not treated by BT. However, as reported in a previous study, 15 no significant decrease in ASM area in the nontreated middle lobe was noted. However, it should be noted that we currently express ASM area as a percentage of the submucosal tissue area, whereas in our previous report 15 the surface area of ASM was calculated as a percentage of the total biopsy area. This and the fact that more patients have been included in this study might explain some variation between our 2 studies. Furthermore, in the middle lobe only 2 biopsy specimens were taken before and after BT, whereas for the treated lobes, 8 biopsy specimens were analyzed before and after BT. Further studies with higher numbers of patients and similar morphologic approaches are needed to determine the effect of BT on the nontreated middle lung lobe. In a subanalysis we observed that the favorable clinical outcome after BT was not consistent in the 15 patients. Indeed, after 12 months, 4 of the 15 patients continued to experience poor asthma control, as attested by ACT and AQLQ scores similar to those measured at entry. This finding might be explained by distinct intrinsic sensitivities of patients with severe asthma to BT, despite apparent clinical similarities, or by an incomplete effectiveness of the procedure on different airway structures. Indeed, our results showing that lower asthma control in response to BT was accompanied by an impaired reduction in ASM area and in the number of neuroendocrine epithelial cells suggest a causal relationship between ablation of these bronchial structural elements and clinical benefit.
Interestingly, numbers of mucosal eosinophils and neutrophils were unchanged, suggesting that clinical improvement induced by BT is unrelated to an effect on granulocytic inflammation. In a recent study, Darcy et al 36 reported a decrease in the bronchoalveolar lavage fluid of transforming growth factor b1 and CCL5 levels 3 and 6 weeks after BT, whereas IL-4, IL-5, and IL-17 levels were unaffected. However, only 11 patients were included in this study, which makes the correlation between these changes and clinical improvement observed after BT difficult to assess.
In conclusion, this is the first study that provides a link between the extent of ASM reduction induced by BT and improvement of disease control in highly symptomatic patients with therapyuncontrolled severe asthma. Importantly, apart from ASM, we identified neuroendocrine epithelial cells, submucosal nerves, and, to a lesser extent, SBM thickening as important targets whose reduction after BT correlated with clinical efficacy.
Whether these airway structural abnormalities need to be downregulated simultaneously by BT to deliver a therapeutic advantage remains to be answered. At this stage, our results support BT as an effective treatment option for severe refractory therapy-uncontrolled asthma and suggest that the clinical benefit is related to alterations in specific airway structures induced by the procedure.
